Comparative Pharmacology
Head-to-head clinical analysis: ENTACAPONE versus TASMAR.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ENTACAPONE versus TASMAR.
ENTACAPONE vs TASMAR
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Entacapone is a selective and reversible inhibitor of catechol-O-methyltransferase (COMT), which inhibits the metabolism of levodopa to 3-O-methyldopa, thereby increasing the plasma half-life and bioavailability of levodopa in the brain.
Selective and reversible inhibitor of catechol-O-methyltransferase (COMT), which increases the bioavailability of levodopa by reducing its peripheral metabolism.
200 mg orally administered concomitantly with each dose of carbidopa/levodopa, up to a maximum of 8 times daily (1600 mg/day).
100 mg orally three times daily; maximum 200 mg three times daily.
None Documented
None Documented
Terminal elimination half-life is approximately 0.4–0.7 hours in the initial phase, with a terminal half-life of 2–2.5 hours, reflecting rapid elimination; clinically, entacapone is administered with each levodopa/carbidopa dose to inhibit COMT.
Clinical Note
moderateEntacapone + Fluticasone propionate
"The risk or severity of adverse effects can be increased when Entacapone is combined with Fluticasone propionate."
Clinical Note
moderateEntacapone + Venlafaxine
"The risk or severity of adverse effects can be increased when Entacapone is combined with Venlafaxine."
Clinical Note
moderateEntacapone + Nefazodone
"The risk or severity of adverse effects can be increased when Entacapone is combined with Nefazodone."
Clinical Note
moderateTerminal elimination half-life is 2–3 hours in healthy volunteers; clinically, this short half-life necessitates three-times-daily dosing to maintain COMT inhibition, though peripheral COMT activity recovers within 4–6 hours.
Primarily hepatic metabolism with biliary excretion: about 90% of dose excreted in feces, 10% in urine (as metabolites).
Primarily hepatic metabolism (glucuronidation and methylation), with approximately 40% of the dose excreted in urine as metabolites and <0.5% as unchanged drug; about 50% is eliminated in feces via biliary excretion.
Category A/B
Category C
COMT Inhibitor
COMT Inhibitor
Entacapone + Stiripentol
"The risk or severity of adverse effects can be increased when Entacapone is combined with Stiripentol."